Clinical trial
A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
NCT01912456 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
- Lead sponsor
- CSL Behring
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- October 31, 2015
- Enrollment
- 90 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.